Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?

References

• National Clinical Guideline Centre2010 Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed February 25, 2017
   Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chronic Obstruct Pulmon Dis20149889904
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017 report Available from: http://goldcopd.orgAccessed March 18, 2017
   Google Scholar
• WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
   PubMed Web of Science ®Google Scholar
• BatemanEFergusonGTBarnesNDual bronchodilation with QVA149 vs. single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed dose combination versus monocomponents in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium and twice daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFAUGMENT COPD Study investigatorsEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• WangLZhaiCJLiuYLiuYJiangSJUmeclidinium plus vilanterol versus placebo, umeclidinium or vilanterol monotherapies for chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trialsClin Drug Investig20163611865875
   Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRFLAME Investigators. Indacaterol-Glucopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• BeehK-MDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)Int J Chron Obstruct Pulmon Dis20161119320526893551
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisonRWISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• HindsDRDiSantostefanoRLLeHVPascoeSIdentification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysisBMJ Open201666e010099
   PubMed Web of Science ®Google Scholar
• HoritaNGotoAShibataYLg-acting muscarinic antagonist (LAMA) plus lon-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKRisk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: a critical review and updateCurr Opin Pulm Med201062118122
   Web of Science ®Google Scholar
• GillessenAHaidlPKohlhäuflMKroegelKVoshaarTGessnerCThe pharmacological treatment of chronic obstructive pulmonary diseaseDtsch Arztebl Int20161131831131627215595
   PubMed Web of Science ®Google Scholar
• DonohueJFHerjeNCraterGRickardKCharacterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot studyInt J Chron Obstruct Pulmon Dis2014974575125053884
   PubMed Web of Science ®Google Scholar
• FattahiFten HackenNHTLöfdahlC-GAtopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP studyRespir Res2013141023356508
   PubMed Web of Science ®Google Scholar
• NiWShaoXCaiXProphylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysisPLoS One2015103e012125725812085
   PubMed Web of Science ®Google Scholar
• DalviPSSinghATrivediHREffect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptomsAnn Thor Med201164221226
   Web of Science ®Google Scholar
• BrillSELawMEl-EmirEEffects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trialThorax2015701093093826179246
   PubMed Web of Science ®Google Scholar
• MartinezFJCurtisJLAlbertRRole of macrolide therapy in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20083333135018990961
   PubMedGoogle Scholar